- Home
- MHUA vs NERV Comparison
MHUA vs NERV Comparison
Compare MHUA & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- NERV
- Stock Information
- Founded
- MHUA 1990
- NERV 2007
- Country
- MHUA China
- NERV United States
- Employees
- MHUA N/A
- NERV N/A
- Industry
- MHUA Medical Specialities
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- MHUA Health Care
- NERV Health Care
- Exchange
- MHUA Nasdaq
- NERV Nasdaq
- Market Cap
- MHUA 11.8M
- NERV 12.0M
- IPO Year
- MHUA 2022
- NERV 2014
- Fundamental
- Price
- MHUA $0.42
- NERV $2.25
- Analyst Decision
- MHUA
- NERV Hold
- Analyst Count
- MHUA 0
- NERV 1
- Target Price
- MHUA N/A
- NERV $5.00
- AVG Volume (30 Days)
- MHUA 147.2K
- NERV 21.0K
- Earning Date
- MHUA 09-19-2025
- NERV 11-04-2025
- Dividend Yield
- MHUA N/A
- NERV N/A
- EPS Growth
- MHUA N/A
- NERV N/A
- EPS
- MHUA 0.40
- NERV 1.48
- Revenue
- MHUA $96,909,642.00
- NERV N/A
- Revenue This Year
- MHUA N/A
- NERV N/A
- Revenue Next Year
- MHUA N/A
- NERV N/A
- P/E Ratio
- MHUA $1.22
- NERV $1.47
- Revenue Growth
- MHUA N/A
- NERV N/A
- 52 Week Low
- MHUA $0.25
- NERV $1.15
- 52 Week High
- MHUA $1.24
- NERV $3.00
- Technical
- Relative Strength Index (RSI)
- MHUA 52.84
- NERV 54.15
- Support Level
- MHUA $0.39
- NERV $2.26
- Resistance Level
- MHUA $0.50
- NERV $2.19
- Average True Range (ATR)
- MHUA 0.04
- NERV 0.12
- MACD
- MHUA 0.00
- NERV -0.03
- Stochastic Oscillator
- MHUA 49.53
- NERV 45.65
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.